We could not find any results for:
Make sure your spelling is correct or try broadening your search.
| Ticker | Name | Price | Change | Change % | Volume |
|---|---|---|---|---|---|
AIXI | XIAO I Corporation | 2.325 | 1.52 | 189.25% | 466,441,555 |
HCAI | Huachen AI Parking Management Technology Holding Company Ltd | 0.3684 | 0.2217 | 151.12% | 439,901,352 |
RDGT | Ridgetech Inc | 0.0334 | 0.0151 | 82.51% | 1,526,031,400 |
CETX | Cemtrex Inc | 1.415 | 0.6193 | 77.83% | 133,294,033 |
MGN | Megan Holdings Ltd | 0.287671 | 0.11747 | 69.02% | 207,414,560 |
HUBC | Hub Cyber Security Ltd | 0.1086 | 0.0346 | 46.76% | 232,438,168 |
ADVB | Advanced Biomed Inc | 6.4657 | 2.05 | 46.28% | 13,572,662 |
SILO | Silo Pharma Inc | 0.5176 | 0.1618 | 45.47% | 149,982,101 |
LNZA | LanzaTech Global Inc | 26.1812 | 8.18 | 45.41% | 94,178 |
LNAI | Lunai Bioworks Inc | 0.4099 | 0.1279 | 45.35% | 120,520,414 |
SKYQ | Sky Quarry Inc | 7.115 | 2.12 | 42.30% | 61,836,450 |
Advancing AI-enabled chemical threat detection and dual-use biodefense technologies through initial commercial deploymentSACRAMENTO, Calif., April 7, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI), an AI-driven drug discovery and biodefense company, today announced that its subsidiary, BioSymetrics, has entered into a revenue-generating, commercial defense-focused collaboration with a specialized biotechnology partner to support the development of an advanced AI-enabled platform for chemical threat assessment, with initial engagement underway and additional engagements currently under discussion.
AstroNova, Inc. (Nasdaq: ALOT or the “Company”), a leading innovator in specialized print technology solutions, today announced that its Board of Directors has initiated a review and evaluation of strategic alternatives to maximize shareholder value. AstroNova will be reporting fourth quarter and fiscal year-end financial results after market on April 13, 2026, followed by a teleconference call at 8:30 a.m. ET on Tuesday, April 14, 2026.
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced enrollment of the first patients in its NANOPULSE-AF study, a prospective, multicenter, IDE pivotal clinical investigation currently evaluating the nPulse™ Cardiac Catheter System for treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation (AF).
Delivers Letter to STIM Board Outlining Potential 5-7x Upside for Shareholders Inherent in Sale of TMS and Standalone Clinic BusinessBLOOMFIELD HILLS, Mich., April 6, 2026 /PRNewswire/ -- Jorey Chernett, the largest independent shareholder of Neuronetics, Inc. (NASDAQ: STIM) (the "Company" or "Neuronetics") owning approximately 14.12% of outstanding shares, today delivered a letter to the STIM Board of Directors (the "Board") calling for the immediate initiation of a comprehensive review of strategic alternatives, including the potential sale of the Company's TMS business.
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions